MiR-133b played tumor suppressing roles in several malignancies through regulating in gastric cancer (58), targeting Sox9 in breast cancer (59), negatively regulating EMP2 in glioma (60), targeting methyltransferase DOT1L in colorectal cancer (61), and targeting EGFR in esophageal squamous cell carcinoma (62). Here, DOT1L is linked to neoplasm.